Clinical Trials Browser

Phase 2 × zanidatamab × Gastrointestinal × Clear all

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07405476 2026-02-12

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Phase 2 Not yet recruiting

38 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07176312 2026-02-04

ZANGEA

Phase 2 Recruiting

80 enrolled

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT07192068 2025-12-19

AcSé HER2

Phase 2 Recruiting

105 enrolled

GastrointestinalHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Sarcoma, Colorectal Neoplasms

NCT07243938 2025-11-24

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

Phase 2 Not yet recruiting

70 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT04466891 2025-09-15

HERIZON-BTC-01

Phase 2 Completed

87 enrolled 25 charts 1 FDA

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT03929666 2025-09-12

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Phase 2 Completed

74 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Clinical Trials

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

ZANGEA

AcSé HER2

Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)

HERIZON-BTC-01

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer